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Objective: Protein arrays are rapidly becoming a powerful means to detect proteins, monitor their
expression levels, and investigate protein interactions and functions. We used this technology and
demonstrated its application in identifying potential biomarkers for the diagnosis and treatment of
interstitial cystitis/painful bladder syndrome (IC/PBS).
Materials and Methods: To compare the expression proﬁles of 40 proteins related to inﬂammation, 30
proteins related to apoptosis, and 20 proteins related to angiogenesis, we performed a protein array assay
using bladder tissues of three normal and six IC/PBS patients and urine samples at the baseline and after
three repeated intravesical onabotulinumtoxinA injections. Different protein expression levels were
determined using the Image J process. After the onabotulinumtoxinA injections, urine samples of IC/PBS
the patient were analyzed using angiogenesis proteins, and results were compared with the untreated
baseline data.
Results: Of all inﬂammatory antigens, 15 were slightly promoted in the IC/PBS patients’ bladder tissues.
Moreover, 80% of proapoptotic proteins and 10% of antiapoptotic proteins on the protein array increased.
We also found that several angiogenesis cytokines decreased in the urine of the IC/PBS patients after the
onabotulinumtoxinA injections.
Conclusion: Our results indicate that several signal transduction pathways are involved in the patho-
physiology of IC/PBS and provide valuable information on the signal networks of different pathways in
IC/PBS, including inﬂammation, apoptosis, and angiogenesis. This is a powerful database to further
investigate molecular mechanisms of IC/PBS.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is
a chronic, painful condition of the bladder wall characterized by
pressure and pain above the pubic area along with increased
frequency of urination and glomerulations in cystoscopic hydro-
distention. In patients with IC/PBS, researchers have found speciﬁc
pathologies, including abnormalities of the urothelium, changes in
the nerve function within the bladder wall, and mast cell over-
activation.1,2 This evidence suggests that several possible patho-
genetic developmental pathways are involved in IC/PBS, including
chronic inﬂammation.3 Histologic studies of tissue biopsies of IC/
PBS patients have consistently reported signs of inﬂammation as
evidenced by degranulation of mast cells and inﬁltration of mast
cells, macrophages, and neutrophils.4Buddhist Tzu Chi General
0, Taiwan.
ciation. Published by Elsevier TaiwOne of the most common ﬁndings in IC/PBS patients is denu-
dation or thinning of the bladder epithelium, suggesting altered
regulation of urothelial homeostasis.1 Our previous reports indi-
cated that the terminal deoxynucleotidyl transferase nick end
labeling (TUNEL)-positive cells were present in the bladder of IC/
PBS patients, and there was a signiﬁcant positive correlation
between mast cell activation and the apoptotic cell number in
bladder tissues of patients with IC/PBS.5 These results suggest that
the urothelium plays a pivotal role as a barrier between the urine
(and its solutes) and the underlying bladder tissues.
During an inﬂammatory response, leukocytes must leave the
vascular lumen and enter the tissue where they perform effecter
functions. Signalingmolecules and cytokines such as tumornecrosis
factor (TNF) and interleukin (IL)-1 cause the expressions of inter-
cellular adhesion molecule (ICAM)-1 and vascular cell adhesion
molecule (VCAM)-1 by neutrophils, which trigger vascular perme-
ability abnormalities or physiologic angiogenesis.6 The cardinal
symptoms and signs of IC/PBS, such as bladder pain, increased
bladder sensation, diffused glomerulations during hydrodistention,an LLC. Open access under CC BY-NC-ND license.
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the diseased bladder wall, and neural upregulation occurs both
peripherally and centrally in the bladders of patients with IC/PBS.7
The clinical presentations of IC/PBS are heterogeneous.2 Patients
with IC/PBS may have predominant bladder pain or predominant
urgency frequency symptoms. Under cystoscopic hydrodistention,
some patientsmay have a reducedmaximumbladder capacity under
anesthesiaormild tosevereglomerulationsorulceration,but somedo
not show these features.8 Although urine and serumbiomarkers such
as nerve growth factor (NGF), C-reactive protein (CRP), anti-
proliferative factor (APF), heparin-binding epidermal growth factor-
like growth factor (HB-EGF), and epidermal growth factor (EGF)
were found to be elevated in IC/PBS1,9e11 not all IC/PBS bladders have
elevatedurinary biomarker levels, although they have typical bladder
pain symptoms and cystoscopic ﬁndings.3,9,10 Increased bladdermast
cell activity9 and proinﬂammatory and apoptotic protein expressions
are also not consistently found in all IC/PBS bladder biopsies.5,12
Recent studies also revealed that the mast-cell density does not
appear to correlate with the duration of symptom amelioration after
complete transurethral resection of Hunner ulcer,13 and overall urine
markers were not associated with biopsy ﬁndings.14 Therefore, we
speculated that histologic ﬁndings, urinary biomarkers, and clinical
presentations in IC/PBS might be heterogeneous.
In this study, we present the preliminary results of a proteomics
analysis of the processes of inﬂammation, angiogenesis, and
apoptosis in IC/PBS bladder tissues and urine samples, and focused
on the crosstalk between different signaling pathways. Based on
the proteomics ﬁndings in IC/PBS bladders, it is possible to link
chronic inﬂammation, urothelial apoptosis, and angiogenesis in IC/
PBS. The results may facilitate future investigations and provide
evidence for therapy targeting chronic inﬂammation in IC/PBS
patients.
2. Patients and methods
Six women with characteristic symptoms of IC/PBS and diffuse
glomerulations but no Hunner ulcer on cystoscopic hydro-
distention were enrolled in this study. Another three women with
stress urinary incontinence without bladder symptoms served as
the controls. Bladder biopsies at three siteswere taken immediately
after cystoscopic hydrodistention for the diagnosis of IC/PBS and
from normal controls during anti-incontinence procedures. No
patient had previously been treated for IC/PBS before the bladder
procedure. Urine samples were also obtained from one patient with
Grade 2 glomerulations at the baseline who received three
repeated intravesical onabotulinumtoxinA (BoNT-A) injections, and
follow-up cystoscopic hydrodistention revealed completely reso-
lution of the glomerulations.
This study was approved by the Institutional Review Board and
Ethics Committee of Buddhist Tzu Chi General Hospital. Each
patient was informed about the study rationale and procedures,
and written informed consent to participate in the study was ob-
tained before we began the bladder procedures.
The IC/PBS patients were classiﬁed by the degree of glomer-
ulations after hydrodistention as Grades 0e3, respectively repre-
senting none, mild, moderate, and severe IC/PBS.2 Specimens with
Grade 2 and 3 (G2 or G3) for glomerulations without an ulcer were
used in this study.
The patients underwent three bladder biopsies at about 2 cm
above the ureteral oriﬁce on the lateral and posterior walls. Each
specimen was 2 mm in diameter, and only bladder mucosa was
obtained. The bladder biopsy specimens were sent to the pathology
department for hematoxylin and eosin staining to exclude the
possibility of carcinoma in situ. Specimens were also stored frozen
in liquid nitrogen for further investigations. The bladder biopsieswere taken at the same sites in the controls and were prepared
using the same methods for comparison.
To compare the expression proﬁles of 30 proteins related to
inﬂammation and 35 proteins related to apoptosis, we performed
a protein array assay on the bladder tissues of normal and IC/PBS
patients and identiﬁed several differentially expressed proteins
using the Image J software (http://rsb.info.nih.gov/ij/index.html).15
After the three BoNT-A injections, urine samples of the IC/PBS
patient were analyzed for 20 angiogenesis proteins, and the results
were compared with untreated baseline data.
2.1. Human apoptosis protein and cytokine antibody array
Extracted protein lysates (250 mg) of control and IC/PBS speci-
mens were incubated on a human apoptosis protein array
membrane (R&D Systems, Minneapolis, MN, USA) at 4C overnight,
washed three times for 5 minutes with a wash buffer, and then
incubated with a horseradish peroxidase (HRP)-linked secondary
antibody diluted 1:2000. After washing, blotted dots were visual-
ized using a Western chemiluminescent HRP substrate (Millipore,
Guyancourt, France). Normalized intensities were calculated from
each array by subtracting the local background from each spot, and
the data were corrected for the protein content in each well. Then
multiples of change in protein expression levels between IC/PBS
and control specimens were calculated.
The human cytokine antibody array procedure (RayBiotech, Nor-
cross, GA, USA) was conducted according to the manufacturer’s
instructions. Brieﬂy, membranes were blocked by incubation with
blockingbuffer at roomtemperature for90minutes.Membraneswere
washed three timeswithwashbuffer I and twotimeswithwashbuffer
II at room temperature for 5 minutes per wash, and incubated with
biotin-conjugated antibodies at room temperature for 90 minutes.
Finally,membraneswerewashedand incubatedwithHRP-conjugated
streptavidin at room temperature for 2 hours. The chemiluminescent
protein dot signals were measured as described above.
To investigate changes in angiogenesis proteins in IC/PBS blad-
ders after three repeated BoNT-A injections, the urine of one IC/PBS
patient was analyzed using an angiogenesis protein array, and the
results were compared with the untreated baseline of the same
patient. The patient exhibited improvement of glomerulations from
Grade 2 to Grade 0 after BoNT-A treatment (Fig. 1A). Two urine
samples were used for the protein array, and 20 molecules for
angiogenesis and vascular inﬂammation were investigated. The
multiples of change in protein expression levels between the
baseline and post-treatment in urine samples of IC/PBS patient
were calculated. The results of the angiogenesis protein array from
urine samples at the baseline and post-treatment might provide
evidence of the effect of intravesical BoNT-A treatment.
2.2. Statistical analysis
The intensities of proteins in the arrays and Western blots were
quantiﬁed using Image J processing.15 Differences in expressions of
inﬂammatory and apoptotic proteins between IC/PBS and control
specimens were analyzed using the Kruskal-Wallis test. All calcu-
lations were performed using SPSS for Windows, version 10.0




The inﬂammatory protein array comprised 30 spots of
inﬂammation-related molecules spotted in duplicate, and positive
Fig. 1. Angiogenesis protein array in an interstitial cystitis/painful bladder syndrome (IC/PBS) patient at baseline and after intravesical onabotulinumtoxinA (BoNT-A) treatment.
Results were compared with the untreated baseline of the same patient. Multiples of changes in protein expression levels between baseline and post-treatment in urine samples of
the IC/PBS patient were calculated. (A) Glomerulations at baseline were Grade 2 and became Grade 0 after treatment; (B) among angiogenesis- and vascular inﬂammatory-related
proteins in the array membrane, 92% were suppressed; (C) protein expressions dramatically decreased after BoNT-A injections, such as vascular endothelial growth factor, platelet
factor 4, interleukin (IL)-1b, IL-8, chemokine (C-X-C motif) ligand 16, and tissue inhibitor of metalloproteinase-4.
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section. We measured the results using Image J software and
identiﬁed molecular changes in inﬂammatory signals. Among the
30 proteins in the array, 14 proteins slightly increased in bladder
tissue lysates of IC/PBS samples compared with the controls,
including IL-10, IL-11, and IL-12; TNF-a signal-related molecules
(sTNFR-I and II), macrophage inﬂammatory proteins (MIPs-1a, b,
and d); ﬁbrosis-associated tissue inhibitors of metalloproteinase
(TIMP)-2; and intercellular adhesion molecule (ICAM)-1 (Fig. 2).
3.2. Apoptotic proteins
To better characterize molecular events leading to apoptosis in
IC/PBS samples, we conducted an apoptosis-related protein-anti-
bodyarrayanalysis of control and IC/PBS specimens. Results showed
that 15 pro- or antiapoptotic proteins were signiﬁcantly modulated
(Fig. 3). Among proapoptotic proteins known to mediate the
apoptotic process, levels of Bax, TRAIL R2, FADD, Fas, and phospho-
p53 increased. Strikingly, some antiapoptotic proteins, such as Bcl-
2, members of the heat shock proteins (HSPs), cyclin-dependent
kinase (CDK) inhibitor, p21, and p27, also signiﬁcantly increased.
3.3. Angiogenesis proteins
After BoNT-A treatment, the urine of the IC/PBS patient was
analyzed using an angiogenesis protein array, and results were
compared with the untreated baseline of the same patient. As shown
in Fig. 1B, 92% of molecules related to angiogenesis and vascular
inﬂammation on the arraymembranewere suppressed. Fig.1C shows
that protein expressions dramatically decreased after the BoNT-A
injections, such as vascular endothelial growth factor (VEGF), platelet
factor 4, IL-1b, IL-8, chemokine (C-X-C motif) ligand 16, and TIMP-4.
4. Discussion
This was a pilot study investigating protein expression proﬁles
of inﬂammation, urothelial apoptosis, and angiogenesis in IC/PBS
patients using a protein array technique. Further conﬁrmative
studies are mandatory in order to explore the heterogeneity of IC/
PBS and mechanisms of therapeutic effects of varying treatment
modalities for IC/PBS.
Previous studies demonstrated that IC/PBS patients have altered
bladder epithelial expressions of HLA-DR and ICAM-a, and secreted
proteins, including IL-1, TNF-a, and various epithelial growth
factors such as HB-EGF, EGF, and IGF1.16e19 Studies on urothelial
dysfunction in IC/PBS also showed altered expressions of certain
tight junction proteins such as zona occludens-1, occluding, and
claudins 1, 4, and 8.20,21 Urine samples from IC/PBS patients also
showed signiﬁcantly decreased HB-EGF and increased levels of EGF,
IGF1, IGFBP3, and cytokines, including IL-6 and IL-8.22 Those ﬁnd-
ings indicate that several inﬂammatory processes are involved in
IC/PBS and are responsible for the clinical symptoms and signs.
Basic research has demonstrated that cardinal signs of inﬂam-
mation such as inﬁltration of mononuclear cells, activation of mast
cells, and neovascularization (angiogenesis) are orchestrated by
chemokines, cytokines, and growth factors in IC/PBS bladders.23,24
During the development of inﬂammation, two major events
occur. Leukocytes interact with the endothelium in a process that
allows these cells to cross the barrier created by endothelial cells.
This cellular migration results in modiﬁcations of the vascular
permeability that permits the transfer of solutes to peripheral
tissues. Under basal conditions, alterations in vascular permeability
are linked to ICAM-1 expression in a protein kinase C (PKC)-
dependent manner.25Matrix metalloproteinases (MMPs) can degrade components of
the extracellular matrix (ECM). Activities of MMPs are inhibited by
tissue inhibitors of metalloproteinases (TIMPs) through formation
of non-covalent 1:1 complexes with MMPs. Four members of the
TIMP family have been characterized so far, designated TIMP-1, -2,
-3, and -4. TIMP-1 is capable of inhibiting the activities of most
MMPs, and plays a key role in maintaining the balance between
ECM deposition and degradation as several inﬂammatory media-
tors are substrates of MMPs. TIMP-1 might affect renal ﬁbrosis via
an inﬂammatory pathway.26
A multitude of vasoactive cytokines, growth factors, and signal
modulators react with endothelial cell substructure components to
control permeability. VEGF, IL-a and -b, TNF-a, and interferon (IFN)-g
were shown to increase endothelial monolayer permeability.27 Lipo-
polysaccharide (LPS) induces junction barrier loss and cell detach-
ment byactivating PTKsand caspase cleavage reactions.28Bycontrast,
junctional adhesion molecules (JAMs) decrease permeability by
initiating cell adhesion. Endothelial cell adhesive characteristics
provide strength and stability for neighboring cells and the cellular
cytoskeleton by interacting with actin and myosin contractile ﬁla-
ments.29 Thrombin stimulation of cytoskeletal signaling pathways
was shown tomanipulate cell permeability. Junctionalmolecules also
inﬂuence cell signaling and trigger responses that are translated into
cell morphological changes and physiological angiogenesis.30
Incubation of human aortic endothelial cells (HAECs) with IL-1a
resulted in increased permeability of quercetin-3-glucuronide.
Furthermore, quercetin-3-glucuronide showed no suppressive effect
on TNF-a-induced cell expression of ICAM-1 by HAECs. MIP-1a is
a member of the C-C subfamily of chemokines, a large superfamily of
low-molecular-weight, inducible proteins that exhibit a variety of
proinﬂammatoryactivities in vitro, including leukocyte chemotaxis.31
Among apoptotic and inﬂammatory proteins, Bad, Bax, caspase 3,
p53, p27, and TNF-a were conﬁrmed by Western blot and statistical
analyses to have higher expression levels in IC/PBS bladders than in
normalbladders.12 In thispilot study, changes inBadandcaspase3did
not reachstatistical signiﬁcance, possiblydue to the small sample size.
Previous research also indicated that phosphorylation of p53 by p38a
can play a role in p53-dependent transcription.32 In addition, p53 is
translocated intomitochondria to interactwithBcl-2orBcl-xl, thereby
activatingBaxdirectlyor indirectly, and leading to caspase-dependent
apoptosis. Previously, evidence showed that the extranuclear role of
p53 in inducing apoptosis is through mechanisms involving Bad and
Bax, which are the main factors that mediate mitochondrial
dysfunction and cell apoptosis.33 Additionally, p53 also participates in
cell cycle arrest through inducing p21 and p27 activities. These
proteins are potential biomarkers for diagnosing IC/PBS. Our ﬁndings
indicate that apoptosis and growth arrest of bladder tissues of IC/PBS
patients could be due to upregulation of inﬂammatory signals.
In addition, TNF-a also promotes apoptosis through binding to
TNF-receptor 1, resulting in many effects ranging from inﬂamma-
tion to apoptosis.34 TNF-a is a pleiotropic molecule that plays
a central role in inﬂammation, apoptosis, and immune system
development.35 Previously, the nature of neurogenic pain was
studied in animal models, and these pain models indicated that
cytokines (TNF-a and NGF) were upregulated in injured nerves, and
neutralizing TNF-a reduced pain behavior.36,37 More exactly, the
primary role of TNF-a is in regulating immune cells, and it can also
induce apoptotic cell death through activation of the transcription
factors, nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-kB) and c-Jun N-terminal kinase.38
Taken together, our protein array results revealed that several
inﬂammatory proteins were signiﬁcantly increased in bladder
tissues of IC/BPS patients, and several proapoptotic and anti-
apoptotic proteins increased. The urine angiogenesis array also
showed decreases in angiogenesis and inﬂammatory proteins after
Fig. 2. (A) Bladder tissue lysates of control and interstitial cystitis/painful bladder syndrome (IC/PBS) specimens were applied to a human inﬂammatory antibody array; (B) spots of each protein refer to the table for the array
coordinates; (C) average density of duplicate spots representing each inﬂammatory protein is expressed in arbitrary units. Seven proteins signiﬁcantly increased in the IC/PBS samples compared with the controls, including intercellular
adhesion molecule, interleukin (IL)-8, IL-6sR, inﬂammatory protein-10, tumor necrosis factor (TNF)-a signal-related molecule (sTFN-R I), sTFN-R II, and tissue inhibitor of metalloproteinase-2. The signiﬁcance of changes in protein














Fig. 3. (A) Bladder tissue lysates of control and interstitial cystitis/painful bladder syndrome (IC/PBS) specimens applied to a human apoptosis protein array. Results are shown after
exposure of the array membranes to X-ray ﬁlm for 1 minute; (B) comprehensive protein membrane-array map. The human protein array simultaneously proﬁles 35 proteins in
duplicate, a set of six positive controls and two negative controls. The average density of duplicate spots representing each pro- and antiapoptotic protein is expressed in arbitrary
units; (C, D) several molecules signiﬁcantly increased in the tissue lysate of the IC/PBS samples, including Bax, TRAIL R2, FADD, Fas, and phospho-p53 (Ser15) in proapoptotic targets,
and Bcl-2, clusterin, H0-2, heat shock protein (HSP) 27, HSP60, HSP70, PON2, p21, and p27 in antiapoptotic targets. The signiﬁcance of changes in protein expression between control
and IC/PBS specimens was determined using the Kruskal-Wallis test. *p < 0.05. **p < 0.005.
J.-H. Shie et al. / Urological Science 23 (2012) 107e113112three repeated intravesical BoNTA injections. These protein
expression proﬁles of inﬂammation, apoptosis, and angiogenesis
suggest a network might exist in the IC/PBS bladder and could
explain the pathophysiology of the clinical features of IC/PBS.
Although this is a small pilot study, the results can provide valuable
evidence for future investigations of heterogeneous pathogenesis
and therapeutic effects of treatments for IC/PBS.
The limitation of this study is the small sample number (six IC/
PBS patients and three controls), and only the bladder mucosa was
harvested. However, because this is a pilot study for the protein
proﬁle study of IC/PBS patients, results of this study can help us
select appropriate proteins for further large-scale investigations of
the pathophysiology and treatment results of IC/PBS.
5. Conclusions
In this study, we describe the ﬁrst ﬁndings obtained by pro-
teomic studies of the molecular mechanisms of IC/PBS, including
correlations among inﬂammation, angiogenesis, and apoptosis. To
further conﬁrm the information obtained from the protein array,
advanced analytical techniques such immunoblotting and enzyme-
linked immunosorbent assay are required. We provide a powerfulresearch protocol for understanding the pathology of IC/PBS, and
even other urologic diseases.
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